Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2015

View Archived Issues

DiamiR receives funding to evaluate microRNA biomarkers for Alzheimer's disease

Sirtex reports preliminary data from the SIRFLOX study

Targazyme and M.D. Anderson Cancer Center to conduct study of TZ-101-treated T Cells

AstraZeneca reports phase III topline results for PT-003

FDA orphan drug designations for two IPF drugs

Universitaet zu Koeln divulges anti-CD30 CAR T cells

Non-toxic mitochondrial protonophore formulation shows potential for T2D and NAFLD/NASH

ALN-TTRSC has clinical activity in TTR cardiac amyloidosis patients

Full results presented from phase III ANNEXA-R study of andexanet alfa

BR-297: a neuroprotective allopregnanolone analogue

Targeting amyloid binding alcohol dehydrogenase with frentizole derivatives

Ignyta acquires four oncology R&D assets from Teva Pharmaceutical

Yisheng Biopharma confirms new vaccine for rabies infection will enter human trials

Scioderm begins phase III trial of Zorblisa in patients with epidermolysis bullosa

Janssen acquires XO1

Can-Fite completes development of biomarker blood test for company's drugs

Heron Therapeutics reports data from phase I study of HTX-011

Amicus Therapeutics reports on meetings with EMA and FDA over migalastat

FDA awards orphan drug designation to Selten's SPI-026 for PAH

Actelion presents new antimalarials

University of Utah describes KDM1A inhibitors

Piramal develops FFAR1 agonists

Purdue Pharma presents new sodium Nav1.7 channel blockers

Evotec and Sanofi establish major strategic alliance

Anthera receives Cystic Fibrosis Foundation Therapeutics award to develop Sollpura

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Rare earth: Biomarin to use global reach post-$4.8B Amicus buy
BioWorld
Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...